Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest
Jeffrey T. Jensen
Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.
Expert Opinion on Pharmacotherapy
Dienogest
Fingerprint Dive into the research topics of 'Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest'. Together they form a unique fingerprint.
estradiol valerate-dienogest Medicine & Life Sciences
Oral Contraceptives Medicine & Life Sciences
Estradiol Medicine & Life Sciences
Menorrhagia Medicine & Life Sciences
Contraceptive Agents Medicine & Life Sciences
Enzyme Activators Medicine & Life Sciences
Hemorrhage Medicine & Life Sciences
Ethinyl Estradiol Medicine & Life Sciences
Jensen, J. T. (2010). Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest. Expert Opinion on Pharmacotherapy, 11(7), 1147-1157. https://doi.org/10.1517/14656561003724713
Evaluation of a new estradiol oral contraceptive : Estradiol valerate and dienogest. / Jensen, Jeffrey T.
In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 7, 01.05.2010, p. 1147-1157.
Jensen, JT 2010, 'Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest', Expert Opinion on Pharmacotherapy, vol. 11, no. 7, pp. 1147-1157. https://doi.org/10.1517/14656561003724713
Jensen JT. Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest. Expert Opinion on Pharmacotherapy. 2010 May 1;11(7):1147-1157. https://doi.org/10.1517/14656561003724713
Jensen, Jeffrey T. / Evaluation of a new estradiol oral contraceptive : Estradiol valerate and dienogest. In: Expert Opinion on Pharmacotherapy. 2010 ; Vol. 11, No. 7. pp. 1147-1157.
@article{1566be54f4c341ae815b47c93c02529d,
title = "Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest",
abstract = "Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.",
keywords = "Contraception, Dienogest, Estradiol valerate, Heavy menstrual bleeding, Menorrhagia",
author = "Jensen, {Jeffrey T.}",
doi = "10.1517/14656561003724713",
journal = "Expert Opinion on Pharmacotherapy",
publisher = "Informa Healthcare",
T1 - Evaluation of a new estradiol oral contraceptive
T2 - Estradiol valerate and dienogest
AU - Jensen, Jeffrey T.
N2 - Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.
AB - Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.
KW - Contraception
KW - Dienogest
KW - Estradiol valerate
KW - Heavy menstrual bleeding
KW - Menorrhagia
U2 - 10.1517/14656561003724713
DO - 10.1517/14656561003724713
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy